Founded in 2023 in Basel, Switzerland, Allegria Therapeutics is building a differentiated portfolio of proprietary molecules that target the pathways driving uncontrolled mast-cell activation. The company’s lead program is advancing toward pre-clinical candidate nomination, while several discovery-stage programs are also progressing. Allegria leverages collaborations with experts such as Prof. Dr. Martin Metz at Berlin’s Charité and Ap. Prof. Dr. Philipp Starkl at the Medical University of Vienna to accelerate its research. Its small but highly experienced core team and advisory board are focused on delivering first-in-class and best-in-disease therapies for allergic and inflammatory conditions. The firm’s recent USD 5.1 million seed extension brings additional capital to support lead-program advancement and discovery efforts, positioning the company for future clinical development milestones.

Total raised

$9M

Funding rounds

2

Latest round

Seed

Latest activity

Dec 2025